Ferring’s novel human recombinant follicle stimulating hormone (human rFSH) Rekovelle has now been launched across the UK for use in controlled ovarian stimulation.
Ferring’s Rekovelle has been approved by European regulators for controlled ovarian stimulation in women undergoing assisted reproductive technologies.
Eight medicines have taken a big leap towards being approved in Europe having won the support of the European Medicines Agency’s Committee for Medicinal Products for Human Use.